Marc Beer, CEO of Renovia, recently decided to roll out the company’s new line of products to help ease the pain that patients with pelvic floor disorders have to deal with. He was able to help raise $32 million for the effort and will guide his company as it continues to develop therapeutic and diagnostic products that focus on treating pelvic floor disorders. The Longwood Fund contributed a good chunk of money to the efforts and is happy to be supporting efforts to help treat rare disorders. Marc Beer commented that Renovia was ecstatic to have the Longwood Fund supporting its efforts and expects to be able to change the lives of million of women who suffer from pelvic floor diseases. These kinds of diseases include urinary incontinence, prolapse, rectocele, chronic prostatitis and chronic pelvic pain, anismus, overflow incontinence, and many other conditions that make life uncomfortable and miserable for many.
Marc Beer is the co-founder of Renovia and also serves as the company’s chairman and chief executive officer. He has over two and a half decades of experience working on the development and marketing aspects of companies in the biotech, pharmaceuticals, diagnostics, and devices industries. Before working with Renovia, he founded ViaCell and became its chief executive officer. During his time with the company, he was able to expand it from its humble beginnings to a large commercial organization with over 300 employees. He took the company public many years later and ended up selling it to PerkinElmer in 2007. Marc Beer serves Minerva Neurosciences Inc. as its chairman of the compensation committee, chairman of the board, and a member of the audit committee. He earned his Bachelor of Science while studying at Miami University in Ohio and continues to serve the educational sector as a member of the Miami University Business Advisory Council.
Before today, he also served as a member of the Notre Dame Research and Commercialization Advisory Committee and Notre Dame Graduate Studies Research and Advisory Council. In the past, Marc Beer has served Erytech Pharma as a member of its board of directors and also worked with Genzyme in many different positions. His last position with the company was vice president of its global marketing efforts. In this position, he was tasked to take care of the commercial launch of a spread of products that help to treat rare diseases. Before working with Genzyme, Marc Beer served Abbot Laboratories in many different marketing and sales positions. He also served as a member of the Mass Life Science Board of the Commonwealth of Massachusetts as well as serving on the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board. It is Beer’s hope to help treat as many people with rare diseases as possible. Learn more : https://www.slideshare.net/MarcBeer